The U.K.-based drugmaker’s Fasenra is now the third respiratory biologic with the option to be self-administered, improving access for patients with severe eosinophilic asthma. It comes as a prefilled, single-use autoinjector.
The treatment, which was originally approved in the U.S. in 2017, is to be used every eight weeks by patients 12 years and older. Self-administration was already approved in the European Union.
Read the full news release here.
More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens
